Should a 20-year-old woman with recurrent urinary-tract symptoms, abnormal menstrual bleeding, and risk for pelvic inflammatory disease receive an intrauterine device now?

IUD Placement Should Be Delayed Until STI Testing and Treatment Are Complete

In this 20-year-old woman with recurrent urinary-tract symptoms, abnormal menstrual bleeding, and risk factors for pelvic inflammatory disease, IUD insertion should be deferred until you have excluded or treated active cervical infections, specifically gonorrhea and chlamydia. 1

Critical Contraindications to Immediate IUD Placement

The CDC Medical Eligibility Criteria assign Category 4 (absolute contraindication) to IUD insertion in women with:

• Current purulent cervicitis 1
• Current chlamydial infection 1
• Current gonorrhea 1

Women who have a very high individual likelihood of STD exposure are assigned Category 3 (generally should not undergo IUD insertion), and insertion should be delayed until appropriate testing and treatment occur. 1

Why This Patient Requires Pre-Insertion Screening

This patient's clinical presentation raises multiple red flags:

• Recurrent urinary-tract symptoms may represent undiagnosed cervicitis or STI rather than true UTI 2
• Abnormal menstrual bleeding can be a manifestation of cervical infection, particularly with chlamydia 2
• Risk factors for PID indicate she may have current or recent STI exposure 1

The absolute risk of PID following IUD insertion is significantly elevated in women with cervical infection at the time of insertion compared to those without pre-existing STIs. 3, 4

Recommended Clinical Approach

Step 1: Test for STIs Before or At Insertion

• Screen for gonorrhea and chlamydia before proceeding with IUD placement 1
• If the patient has not been screened according to CDC STD Treatment Guidelines, screening can be performed at the time of IUD insertion, and insertion should not be delayed if she has no clinical signs of purulent cervicitis 1
• However, given this patient's symptoms and risk factors, testing before insertion is the safer approach 5

Step 2: Perform Bimanual Examination and Cervical Inspection

• Bimanual examination and cervical inspection are Class A (essential and mandatory) examinations before IUD insertion 1
• Look specifically for purulent cervical discharge, cervical motion tenderness, or adnexal tenderness 2
• If purulent cervicitis is present on examination, do not insert the IUD regardless of test results 1

Step 3: Treat Any Identified Infections Before Insertion

• If gonorrhea or chlamydia is detected, treat with appropriate antibiotics according to CDC STD Treatment Guidelines before IUD insertion 1
• Complete treatment and ensure clinical resolution before proceeding with IUD placement 5

Risk of Infection After IUD Insertion

The risk of PID is highest in the first 20 days after IUD insertion, with approximately 6 pelvic infections per 1000 woman-years of IUD use. 6, 5 This risk is primarily related to the mechanical disruption of the cervical barrier during insertion, which allows bacteria present in the lower genital tract to ascend to the upper genital tract. 3

Among women who had an IUD inserted with an STI present at the time of insertion, the absolute risk of subsequent PID was low but significantly greater than among women without STI at insertion. 1

Management If IUD Is Already in Place and PID Develops

If this patient already has an IUD and develops PID:

• Treat with appropriate antibiotics for PID 1
• The IUD usually does not need to be removed if the woman wishes to continue using it 1
• Clinical course does not differ whether the IUD is removed or left in place during PID treatment 1, 3
• Reassess after 2-3 days of treatment 1

Important Caveats

• Routine antibiotic prophylaxis is not recommended prior to IUD insertion in low-risk women 5
• Bacterial vaginosis screening is not routinely recommended in asymptomatic women 5
• The overall rate of PID among all IUD users is low when appropriate screening and patient selection are performed 1
• IUDs remain one of the most effective reversible contraceptive methods and should not be unnecessarily withheld, but safety requires excluding active cervical infection first 7, 6